Drugs / EBV gH/gL/gp42-ferritin nanoparticle vaccine
EBV gH/gL/gp42-ferritin nanoparticle vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06908096 | May 2025 → Oct 2027 expected | infectious mononucleosis | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBV gH/gL/gp42-ferritin nanoparticle vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06908096 ↗ |
| Modality | Vaccine | “This is a phase 1 study to evaluate the safety of a 3-dose vaccination regimen of an EBV gH/gL/gp42-ferritin nanoparticle vaccine with or without gp350-ferritin.” NCT06908096 ↗ |
| Route | Intramuscular | “The adjuvanted gH/gL/gp42-ferritin nanoparticle vaccine is given with gp350-ferritin intramuscularly into the deltoid muscle” NCT06908096 ↗ |